EUROPEAN COMMISSION

Brussels, 18.1.2024
C(2024) 443 final

PUBLIC VERSION

Ardian France S.A.
20, Place Vendôme
75001 Paris
France

Subject: **Case M.11377 – ARDIAN / DEDALUS HEALTHCARE SYSTEMS**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004[1] and Article 57 of the Agreement on the European Economic Area[2]

Dear Sir or Madam,

1. On 15 December 2023, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation, by which the undertaking Ardian France S.A. ('Ardian', France), ultimately controlled by the parent company of the Ardian Group, Ardian Holding S.A.S. (France), will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the whole of the undertaking Dedalus Healthcare Systems Group S.p.A. ('DHSG', Italy), currently jointly controlled by HealthLux S.A. ('HealthLux', Luxembourg, controlled by Ardian) and Health Holding Company S.r.l. ('HHC', Italy) by way of purchase of shares.[3]

2. The business activities of the undertakings concerned are the following:

   – Ardian is a private equity investor and asset manager,

   – DHSG is the holding company of the Dedalus Group, a pan-European group producing and selling software for the healthcare, medical, diagnostic and pharmaceutical sector.

1 OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

2 OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').

3 Publication in the Official Journal of the European Union, OJ C, C/2023/1638, 22.12.2023.

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraphs 5(d) and 5(e) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004.[4]

4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General

4 OJ C 160, 5.5.2023, p. 1–10.